Pinealon: EDR Identity, Evidence and Dose References

Quick Reference Card

Why the protocols disagree

The oral capsule listings describe finished supplement products and peptide complexes. The vial pages describe lyophilized research material and syringe arithmetic. The animal paper describes a specialized prenatal rat model. Those categories cannot be merged into one "typical Pinealon dose." [3][4][7][11][12]

The older human claims summarized in reviews also do not solve the dosing question. They are not modern, independently replicated, blinded dose-ranging trials, and the public summaries often do not expose all design details needed for clinical interpretation. [1][9][10]

What is Pinealon?

Pinealon is EDR, a three-amino-acid peptide from the Khavinson short-peptide bioregulator literature. The name can be misleading: it is discussed in neuroprotection and aging contexts, while several commercial explanations blur brain cortex, pineal, Cortexin and Cytogen product lineages. The chemically relevant identity is Glu-Asp-Arg. [1][2]

The capsule market adds another identity layer. PeptideProduct lists Pinealon capsules with AC-5 peptide complex and states that two or four capsules provide 20 mg or 40 mg of peptide complex. iPept describes AC-5 plus amino acids. That does not prove that every capsule, spray or vial provides a verified amount of pure EDR with equivalent absorption. [3][4]

Pathway visualization

The 2024 laboratory study found changes in dendritic morphology, without improved mitochondrial or lysosomal activity. Its EDR DNA-damage result, p=0.0566, remains exploratory. These are cultured-cell findings, not evidence of cognitive or sleep benefits in people. [13]

Mechanism of action

The 2011 Rejuvenation Research paper reported that Pinealon restricted reactive oxygen species accumulation in cerebellar granule cells, neutrophils and PC12 cells under oxidative stress, decreased necrotic cell death and altered ERK1/2 activation timing. The authors inferred possible genome interaction, but inference should not be stated as proven human mechanism. [6]

A fluorescence-labeled peptide study found cytoplasmic, nuclear and nucleolar fluorescence in HeLa cells after incubation with labeled Pinealon and related short peptides. It also reported sequence-dependent effects on labeled oligonucleotides and DNA complexes. These results support a biophysical hypothesis for nuclear interaction, but they are in vitro findings. [8]

The 2020 Molecules review discusses EDR in Alzheimer's-related pathways, including oxidative stress, apoptosis markers and gene-expression models. A review is useful for mapping mechanisms, but it is not a clinical trial showing cognitive or sleep benefits. [1]

What the evidence shows

Cell and animal studies

The strongest direct evidence is preclinical. The 2011 cell paper supports ROS and cell-survival hypotheses under laboratory stress conditions. The 2012 rat offspring study reported better Morris water-maze performance and lower oxidative-stress and necrotic-cell signals in offspring from methionine-loaded dams treated with Pinealon. These are not human cognition or sleep trials. [6][7]

A 2024 study exposed fibroblast-derived neurons from older donors to EDR and related peptides at 10 mcg/mL for 10 days. Dendritic branching increased, but mitochondrial/lysosomal activity and p16/lamin B1 markers did not improve. The reported EDR oxidative-DNA-damage result had p=0.0566, above the usual 0.05 threshold, despite stronger language elsewhere in the paper. This remains exploratory cell-culture evidence. [13]

Human claims

The 2020 review states that oral Pinealon was used in older-age cerebral dysfunction contexts and describes a 72-patient post-TBI/cerebrasthenia observation with reported improvements in memory, headaches, emotional balance and performance. These observations provide low-certainty human context because the modern public record does not provide an independently replicated RCT with transparent blinding, randomization and replication. [1][9]

No current ClinicalTrials.gov record for Pinealon was found during the September 2026 refresh. Public 2026 reviews similarly report no completed modern randomized human trials and no visible ClinicalTrials.gov program for Pinealon. [10][14]

Safety, interactions and product handling

No formal human pharmacokinetic study was found for Pinealon by any route. That leaves basic questions open: intact oral absorption, nasal or sublingual bioavailability, injectable exposure, degradation products, tissue distribution and repeat-course safety. [9][10]

Safety claims based on "short peptides are natural" are not enough. Product-specific risks include incorrect identity, concentration error, contamination, solvent issues, sterility problems, excipients, storage degradation and route mismatch. Mechanistic papers do not validate a consumer vial or capsule. [3][4][10]

Benefits for sleep, circadian rhythm, REM sleep, mood and cognitive performance remain unproven. No polysomnography, actigraphy, validated insomnia scale or independent cognition trial was found that establishes Pinealon for those outcomes. [9][10]

Connecting research with a useful record

A Pinealon log is clearest when it separates oral capsules, vial material, sublingual drops and nasal products. The Doserly App can record the route, source, amount on the label, schedule and observations together, which makes it easier to avoid mixing a Cytogen capsule course with a research-vial protocol.

Doserly Academy can help interpret why cell, rat and induced-neuron findings support mechanism discussion but do not establish a personal sleep, cognition or longevity protocol.

Frequently asked questions

Is Pinealon the same as Epitalon?

No. Pinealon is EDR, while Epitalon is AEDG. They come from the same general research tradition, but their identities and evidence should not be merged. [1][13]

Is Pinealon proven to improve sleep?

No. Sleep-related claims appear in secondary summaries and public discussion, but no direct controlled sleep trial using objective sleep measures was found. [9][10]

Is there an established injectable dose?

No. Online vial protocols list amounts from hundreds of micrograms to milligrams, but they are not clinical dose-ranging studies or labels. [11][12]

Do capsule labels prove pure EDR exposure?

No. Some capsule listings report peptide complex amounts such as AC-5, not a verified pure EDR mass or human pharmacokinetic exposure. [3][4]

Are there current registered clinical trials?

No current ClinicalTrials.gov Pinealon record was found during this refresh. Absence from one registry does not prove no study exists anywhere, but it does show no visible modern registry-backed program in that database. [14]

References

[1] EDR peptide mechanisms in Alzheimer's disease, Molecules 2020

[2] Pinealon increases cell viability by suppression of free radicals

[3] PeptideProduct: Pinealon Cytogens capsule listing

[4] iPept: Pinealon capsule listing

[5] Peptide Commons: Pinealon profile

[6] Khavinson et al. Pinealon cell study, 2011

[7] Pinealon protects rat offspring from prenatal hyperhomocysteinemia

[8] Short fluorescence-labeled peptides penetrate HeLa-cell nuclei

[9] Peptides Media: Pinealon evidence summary

[10] Superpower: Pinealon research guide

[11] PeptideDosages: Pinealon 20 mg vial protocol

[12] PeptaBase: Pinealon protocol profile

[13] Short peptides protect fibroblast-derived induced neurons from age-related changes

[14] ClinicalTrials.gov search portal